[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"relapsedrefractory-acute-myeloid-leukemia-aml\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:relapsedrefractory-acute-myeloid-leukemia-aml":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,40,67,91,113,138,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100644928","early-phase-1-a-clinical-study-to-investigate-the-safety-and-efficacy-of-off-the-shelf-inkt-cell-injection-targeting-cd33cd70-in-adult-patients-with-relapsedrefractory-acute-myeloid-leukemia-100644928",false,"NCT07676006","A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33\u002FCD70 in Adult Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia","Inclusion Criteria:\n\n* 1\\. Voluntarily participate in this clinical study, fully understand the study content, sign the informed consent form, and be willing to comply with all study procedures and complete all follow-up visits.\n* 2\\. Aged between 18 and 75 years old (inclusive), with no restriction on gender.\n* 3\\. Confirmed diagnosis of relapsed\u002Frefractory acute myeloid leukemia (AML) per the 2016 WHO Classification, with the specific definitions as follows:\n\nConfirmed AML with bone marrow blasts ≥5% at screening, and meeting any one of the following criteria:\n\n* Relapsed disease: Relapse after achieving complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) following standard induction chemotherapy;\n* Refractory disease: a) Failure to achieve CR\u002FCRi after 2 cycles of induction chemotherapy; b) Relapse within 12 months of first remission with no response to subsequent re-treatment; c) Relapse after autologous or allogeneic hematopoietic stem cell transplantation; d) Failure to achieve CR\u002FCRi after at least two lines of salvage therapy.\n\n  * 4\\. Confirmed positive expression of CD33 or CD70 via flow cytometry and\u002For immunohistochemistry.\n  * 5\\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n  * 6\\. Estimated survival of more than 12 weeks.\n  * 7\\. Toxicities resulting from prior therapies must be stabilized and recovered to Grade ≤1 (alopecia and other toxicities with no significant clinical impact are excluded).\n  * 8\\. Adequate hepatic, renal, pulmonary and cardiac function, meeting the following specific criteria:\n  * o Estimated creatinine clearance (calculated via the Cockcroft-Gault formula) ≥60 mL\u002Fmin;\n  * o Serum alanine aminotransferase\u002Faspartate aminotransferase (ALT\u002FAST) ≤2.5 times the upper limit of normal (ULN);\n  * o Total bilirubin ≤1.5 mg\u002FdL (participants with Gilbert's syndrome excluded from this criterion);\n  * o Cardiac ejection fraction ≥50%, no evidence of pleural effusion on echocardiogram (ECHO), and no clinically significant abnormalities on electrocardiogram (ECG);\n  * o Absence of clinically significant pleural effusion;\n  * o Baseline oxygen saturation \\>92% while breathing room air.\n  * 9\\. Females of childbearing potential: Serum or urine pregnancy test negative at screening (subjects with surgical sterilization or menopause for ≥2 years are not considered of childbearing potential). Must agree to use highly effective and reliable contraception for 1 year after receiving study treatment, and refrain from oocyte donation.\n  * 10\\. Male participants: If sexually active with females of childbearing potential, must agree to use highly effective and reliable contraception for 1 year after receiving study treatment, and refrain from sperm donation.\n\nExclusion Criteria:\n\n* 1\\. Prior history of central nervous system (CNS) leukemia; or intracranial magnetic resonance imaging (MRI)\u002FPET-CT at screening suggestive of CNS leukemia; or malignant cells identified in cerebrospinal fluid (CSF).\n* 2\\. Other untreated malignant neoplasms diagnosed within the past 5 years or concurrent malignancies (Exceptions: adequately treated cervical carcinoma in situ, localized cutaneous squamous cell carcinoma, basal cell carcinoma, localized prostate cancer, ductal carcinoma in situ of the breast, urothelial carcinoma ≤T1; participants with prostate cancer under active surveillance are eligible).\n* 3\\. Prior receipt of CD33- or CD70-targeted cellular therapies including CAR-T, NK or iNKT cells (Excluding subjects previously treated with GT737 who qualify for re-treatment).\n* 4\\. Systemic corticosteroids administered within 7 days prior to cell infusion (Exceptions: inhaled corticosteroids and subjects with prior allogeneic transplantation history).\n* 5\\. History of hypersensitivity to any component of investigational products to be used in this study, including but not limited to GT737 cell infusion product, cyclophosphamide and fludarabine.\n* 6\\. Uncontrolled suspected or confirmed fungal, bacterial, viral or other infections, or infections requiring intravenous (IV) antimicrobial therapy (Excluding prophylactic antimicrobial treatment).\n\n  7\\. Positive test results for any of the following: human immunodeficiency virus (HIV) antibody, Treponema pallidum antibody, cytomegalovirus IgM (CMV-IgM), Epstein-Barr virus IgM (EBV-IgM).\n* 8\\. Active hepatitis B (positive HBV-DNA) and\u002For active hepatitis C (positive HCV RNA).\n\nParticipants positive for HBsAg\u002FHBcAb must undergo HBV-DNA testing; those with negative HBV-DNA may be enrolled. Post-enrollment, prophylactic antiviral therapy shall be administered if clinically indicated per investigator assessment.\n\nSubjects with negative HCV antibody are eligible for enrollment. Participants with positive HCV antibody must receive HCV RNA testing and may be enrolled only if HCV RNA is negative.\n\n* 9\\. Presence of any indwelling line or drainage tube (Exceptions: dedicated central venous access catheters such as Port-a-Cath and Hickman catheter).\n* 10\\. Current or prior central nervous system disorders including seizures, cerebral ischemic\u002Fhemorrhagic events, dementia, cerebellar disease, or any autoimmune disease involving the CNS.\n* 11\\. Cardiac involvement secondary to acute myeloid leukemia.\n* 12\\. Occurrence of any of the following within 6 months prior to signing the informed consent form:\n\n  * Uncontrolled congestive heart failure (New York Heart Association Class III-IV), angina pectoris, myocardial infarction, cardiomyopathy;\n  * Stroke (Excluding lacunar infarction), coronary or peripheral artery bypass graft surgery;\n  * Clinically significant arrhythmias (e.g., ventricular arrhythmia), markedly prolonged QT interval (corrected QTc ≥500 ms by Bazett's formula, as judged by the investigator);\n  * Uncontrolled hypertension (systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100 mmHg), uncontrolled diabetes mellitus;\n  * Pulmonary embolism, diffuse pulmonary infiltrates, impaired pulmonary function;\n  * Other medical conditions deemed unsuitable for study participation by the investigator.\n* 13\\. Anticipated or potential need for emergency treatment within 6 weeks due to ongoing or imminent oncologic emergencies (e.g., tumor mass effect, tumor lysis syndrome).\n* 14\\. Primary immunodeficiency disorders.\n* 15\\. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months before enrollment requiring systemic anticoagulation therapy.\n* 16\\. Any medical condition that may interfere with the assessment of safety or efficacy of the study treatment.\n* 17\\. Live attenuated vaccines or mRNA vaccines administered within 8 weeks prior to lymphodepleting conditioning; inactivated vaccines administered within 4 weeks prior to lymphodepleting conditioning.\n* 18\\. Females of childbearing potential who are pregnant or breastfeeding (Subjects with surgical sterilization or menopause for ≥2 years are not regarded as of childbearing potential).\n* 19\\. Male or female participants unwilling to use contraceptive measures from the time of informed consent through 6 months after completion of study treatment.\n* 20\\. Participants judged by the investigator to be unlikely to complete all study visits and procedures (including follow-up) or unable to comply with study participation requirements.\n* 21\\. History of autoimmune disease within the past 2 years causing end-organ damage or requiring systemic immunosuppressive agents\u002Fsystemic disease-modifying therapy (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, etc.).","ALL","18 Years","75 Years",{"count":19,"type":20},36,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","This is a single-arm, open-label, dose-escalation, prospective exploratory clinical study intended to evaluate the safety, efficacy and cellular pharmacokinetics of GT737 cells in adult patients with relapsed\u002Frefractory acute myeloid leukemia (AML).",[26],"Relapsed\u002FRefractory Acute Myeloid Leukemia (AML)","NOT_YET_RECRUITING","2026-06-29",{"date":30,"type":31},"2026-06-30","ACTUAL",{"date":33,"type":20},"2026-07-01",{"date":35,"type":20},"2030-06",{"name":37,"class":38},"Grit Biotechnology","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":50,"conditions":51,"keywords":52,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":39},"100642952","individualized-aml-treatment-100642952","NCT07613385","Individualized AML Treatment","Feasibility Study of Individualized Treatment Recommendations for Acute Myeloid Leukemia Based on High Throughput Screening and Genomics Data","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative.\n* Agreement to allow the use of archival tissue from diagnostic tumor biopsies\n* Age: ≥ 18 years\n* ECOG ≤ 3 (Appendix A)\n* Patients with histologically confirmed AML according to ICC or WHO criteria, and\n* Refractory\u002Frelapsed (R\u002FR) to prior treatment with one or more regimens if adverse risk or two or more regimens if favorable\u002Fintermediate risk (Appendix B)\n* Sufficient bone marrow and\u002For peripheral blood sample (archival or fresh) to run the high throughput screening (HTS; Estimate sufficient if circulating blast count of 5,000 or greater or cellular marrow with greater than or equal to 20% blasts.) Otherwise,\n* Sufficient cells flushed from bone marrow biopsy, if bone marrow is not aspirable, OR\n* Extramedullary disease, if it is possible to obtain a fluid or biopsy sample from that location\n* Expected survival is greater than 100 days.\n* Fully recovered from the acute toxic effects (except alopecia) to ≤ Grade 1 to prior anti-cancer therapy\n\nExclusion Criteria:\n\n* Treatment with any chemotherapeutic agent necessary to control AML burden is permitted between day -18 and -1.\n* Must not have received or planning to receive live vaccine while being on study\n* Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (FAB class M3-AML)\n* Active central nervous system (CNS) disease (OK if treated and responding)\n* Active graft vs host disease (GVHD)\n* Unstable cardiac disease as defined by one of the following:\n* Cardiac events such as myocardial infarction (MI) within the past 6 months\n* Uncontrolled atrial fibrillation or hypertension\n* Clinically significant uncontrolled illness\n* Uncontrolled active infection\n* Females only: Pregnant or breastfeeding\n* Any other condition or active malignancy that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics).",{"count":48,"type":20},18,"OBSERVATIONAL","Every patient responds differently to their cancer treatment, and some treatments work better for some patients more than others. For patients with relapsed, refractory ( R\u002FR) AML, there may be fewer approved treatment options remaining. In this research study, the investigators are testing whether high throughput drug screening (HTS) in combination with robust molecular testing by HopeSeq (includes DNA sequencing for \\>500 genes and 160 gene rearrangements and RNAseq for \\>5,000 genes) can help doctors determine which treatment might work best for each individual patient. HTS tests how the patient's own AML cells respond to different treatment options including individual drugs and triple drug regimens and recommends for the best treatment options for an individual patient. Participants will provide extra bone marrow and\u002For blood at the time of routine procedure, and these extra sample(s) will be tested using the Cancer Drug Sensitivity Test ( CDST) HTS, CLIA approved in Washington state since 2014. A committee (the Functional Molecular Tumor Board) will review the HopeSeq and HTS results, past treatments, and clinical description, and give a recommendation for the best AML treatment options for each individual patient. The patient's doctor will get a copy of the recommendation and discuss treatment options with the patient. The patient and their doctor will decide on the best treatment plan for the patient, one which will be approved by insurance. Patients will not be treated with any drugs as part of this study. Then at 6 and 12 months, there will be retrospective review of medical records to determine how will the testing predicted the response, drug sensitivity or resistance, and overall and disease-free survival will be monitored.",[26],[53,54,55],"Feasibility study","Acute myeloid leukemia","Individualized treatment","RECRUITING","2026-06-12",{"date":59,"type":31},"2026-06-15",{"date":61,"type":31},"2026-01-01",{"date":63,"type":20},"2028-06-01",{"name":65,"class":66},"City of Hope Medical Center","OTHER",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100450323","phase-1-cln-049-in-patients-with-relapsedrefractory-acute-myeloid-leukemia-aml-or-myelodysplastic-syndrome-mds-100450323","NCT05143996","CLN-049 in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","Inclusion Criteria:\n\n1. Aged ≥ 18 years of age.\n2. Willing and able to give written informed consent and adhere to protocol requirements; written informed consent and any locally required authorization must be obtained from the patient prior to performing any protocol-related procedures, including screening evaluations, and serial samples of bone marrow and peripheral blood.\n3. Patient has a confirmed diagnosis of recurrent or refractory AML or MDS.\n4. Patient has received, and has progressed, recurred, or is intolerant of approved therapeutic options that are available, or declines treatment with these therapies.\n5. White blood cell (WBC) count at the time of the first dose is \\\u003C 20,000\u002FuL (hydroxyurea is permitted according to standard institutional practice). Following first dose, WBC should be checked prior to subsequent CLN-049 administration and if WBC \\> 20,000\u002FμL, CLN-049 treatment should be postponed (see Section 6.1 for further guidance).\n6. Eastern Cooperative Oncology Group (ECOG) performance status is 0 to 2.\n7. Toxicities related to prior study therapy should have resolved to Grade 1 or less according to criteria of NCI CTCAE v5.0, except for alopecia, lymphopenia, neutropenia, leukopenia, anemia, thrombocytopenia. Patients with chronic but stable toxicities may be allowed to enroll after agreement between the Investigator and Sponsor.\n8. The patient's laboratory values meet the following criteria:\n\n   1. Creatinine clearance (CrCl) as calculated by the Cockcroft-Gault formula (Appendix 1) must be ≥ 60 mL\u002Fmin;\n   2. Total bilirubin ≤ 1.5 × ULN. This does not apply for patients with confirmed Gilbert's Syndrome, hemolysis, or chronic blood transfusions, for whom total bilirubin must be less than 3.0 mg\u002FdL with a conjugated bilirubin less than 0.5 mg\u002FdL;\n   3. AST and ALT ≤ 3.0 × ULN (unless attributed to leukemic involvement).\n\nExclusion Criteria:\n\n1. Diagnosis of acute promyelocytic leukemia (APL)\n2. Active central nervous system (CNS) leukemia. For patients with a history of CNS leukemia, a lumbar puncture should be performed during screening to exclude the presence of active CNS involvement.\n3. Isolated extramedullary relapse\n4. Prior organ allograft\n5. Allogeneic hematopoietic transplantation within six months of treatment, or with clinical or laboratory evidence of GVHD, or requiring ongoing treatment with immune suppression within 2 months of the first dose of CLN-049.\n6. Treatment with any of the following:\n\n   1. Radiation therapy (XRT) within 28 days of the first dose of CLN049, or craniospinal XRT within 8 weeks of the first dose of CLN-049, or history of total body irradiation (TBI).\n   2. Prior immunotherapy with checkpoint inhibitors ≤ 42 days prior to the first dose of CLN-049.\n   3. Prior history of chimeric antigen receptor (CAR-T) cell therapy or other modified T cell therapy.\n   4. Anti-leukemic therapy except hydroxyurea for cytoreduction, and intrathecal chemotherapy ≤ 14 days or 5 half-lives, whichever is shorter, prior to the first dose of CLN-049.\n   5. Short-acting hematopoietic growth factors ≤ 7 days prior to the first dose of CLN-049\n   6. Long-acting growth factors ≤ 14 days prior to the first dose of CLN-049.\n   7. Systemic glucocorticoid therapy (except equivalent of \\\u003C 10 mg prednisone daily) or other immune-suppressive drugs ≤ 14 days prior to the first dose of CLN-049 (see separate guidelines for patients who are post allogeneic hematopoietic transplantation). The transient use of corticosteroids for transfusion premedication or the treatment of infusion or transfusion reactions will not be considered for this criterion. Topical corticosteroids and steroid eye drops are allowed, and will not exclude the patient from eligibility.\n   8. Prior treatment with a FLT3-directed bispecific molecule, or a FLT3-targeted antibody.\n7. Currently participating\u002Fpreviously participated in an interventional study and received an investigational drug within 14 days (or five half-lives, whichever is longer) prior to the first dose of CLN-049.\n8. Patients with concomitant second malignancies requiring active treatment in the past 12 months, or if additional therapy is required or anticipated during study participation.\n9. Patients with any active autoimmune disease or a history of known or suspected autoimmune disease, or history of a syndrome that requires systemic corticosteroids or immunosuppressive medications, except for patients with vitiligo, psoriasis (in consultation with the Sponsor), resolved childhood asthma\u002Fatopy or autoimmune thyroid disorders on stable thyroid hormone supplementation.\n10. A serious uncontrolled medical disorder that would impair the ability of the patient to receive protocol therapy or whose control may be jeopardized by the complications of this therapy.\n11. Any concurrent condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might compromise patient safety or interfere with the evaluation of the safety of the drug.\n12. Active uncontrolled infection within seven days of first dose of CLN-049. Prophylactic use of systemic antiviral, antibacterial, or antifungal agents for treatment of chronic, controlled infection or as prophylaxis is permitted.\n13. Has a history of, or a positive test for Human Immunodeficiency Virus (HIV) 1\u002F2 or primary immunodeficiency disease such as HIV.\n14. Known history of hepatitis B (with positive testing for either hepatitis B surface antigen \\[HBsAg\\] or hepatitis B core Ab), hepatitis C (HCV) infection (with positive testing for HCV antibody and\u002For HCV ribonucleic acid \\[RNA\\] in serum), or acute hepatitis A (with positive testing for hepatitis A IgM). Note: patients with chronic HCV with undetectable viral load defined by sustained virologic response 24 weeks (SVR24) after completion of anti-hepatitis C treatment will be eligible. Patients with hepatitis B surface antigen \\[HBsAg\\] or hepatitis B core Ab with negative viral load will be eligible.\n15. Active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection including history of positive SARS-CoV-2 testing without subsequent documentation of negative test results, patients with results that are pending but not yet known, or patients with suspected active infection based on clinical features\n16. History of the following events in conjunction with prior treatment with immunotherapy: Grade 3 or greater neurotoxicity, ocular toxicity, pneumonitis, myocarditis, or colitis; liver dysfunction meeting the laboratory criteria for Hy's Law.\n17. Live virus vaccines within 28 days of the first dose of CLN-049, during treatment, and until the end of last dose of CLN-049.\n18. Woman of child-bearing potential (WOCBP) who is pregnant or breast-feeding, plans to become pregnant within 120 days of last study drug administration, or declines to use an acceptable method to prevent pregnancy during study treatment and for 120 days after the last dose of study drug administration.\n19. Male patient who plans to father a child or donate sperm within 120 days of last study drug administration, or who has a partner who is a WOCBP, and declines to use acceptable method to prevent pregnancy during study treatment and for 120 days after the last dose of study drug administration.\n20. QT interval corrected for heart rate using Fridericia's formula (QTcF) of ≥ 480 milliseconds.\n21. Patient has history of drug-related anaphylactic reactions to any components of CLN-049. History of Grade 4 anaphylactic reaction to any bispecific molecule or monoclonal antibody therapy.\n22. Known history of prior human anti-human antibody response. Patients will not be screened for human anti-human antibody prior to study participation.\n23. Known active alcohol or drug abuse.\n24. Patients who are incapacitated or involuntarily incarcerated.",{"count":75,"type":20},60,[77],"PHASE1","CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed\u002FRefractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)",[26,80],"Myelodysplastic Syndrome (MDS)","2026-01-14",{"date":83,"type":31},"2026-01-16",{"date":85,"type":31},"2021-11-18",{"date":87,"type":20},"2027-06",{"name":89,"class":38},"Cullinan Therapeutics Inc.",11,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":4},"100599445","phase-1-an-open-label-dose-escalation-and-dose-expansion-study-of-gb3226-in-patients-with-relapsedrefractory-acute-myeloid-leukemia-100599445","NCT07084584","An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia","A Phase 1\u002F2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of GB3226 in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia","Eligible participants are males and female aged 18 years or older at screening with relapsed or refractory acute myeloid leukemia Diagnosis\n\n1. Patients in Phase 1 must have active acute myeloid leukemia (bone marrow blasts ≥5% or reappearance of blasts in peripheral blood) as defined by the National Comprehensive Cancer Network (NCCN) in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines, Version 3.2024).\n2. Phase 2 patients must have documented active acute leukemia (bone marrow blasts ≥5% or reappearance of blasts in peripheral blood) as defined by the NCCN Guidelines for Acute Myeloid Leukemia (Version 3.2024) and may have specific genetic profiles.\n\n   For Phase 2, if inclusion is restricted to specific genetic subtypes, mutational status will be assessed locally for initial eligibility determination and confirmed by central laboratory testing. Patients with mutational status not confirmed centrally, or with final pathology or flow cytometry reports indicating \\\u003C5% bone marrow blasts, will be replaced to ensure adequate enrolment for the primary efficacy analyses.\n\n   Disease Status\n3. Recurrent or refractory AML, as defined by standardized criteria (for example, European LeukemiaNet criteria (Döhner 2022); International Working Group criteria (Cheson 2003)) after standard of care therapy, including but not limited to one or two cycles of intensive chemotherapy, or venetoclax combinations. Patients with persistent leukemia after initial therapy or with recurrence of leukemia at any time after achieving a response during or after the course of treatment (including allogeneic HSCT) are eligible. Refractory or relapsed leukemia is defined by presence of ≥5% blasts in the bone marrow and\u002For persistence or reappearance of peripheral blasts. Patients who, upon central review, have \\\u003C5% blasts in the bone marrow at baseline may be replaced to ensure enough patients for the efficacy analyses.\n\n   In addition, all patients must have:\n4. White blood cell (WBC) count below 25,000\u002FμL at time of enrolment. Patients may receive cytoreduction prior to enrolment per Inclusion Criteria 12 and 15\n5. Male or female patients aged ≥18 years of age\n6. Eastern Cooperative Oncology Group (ECOG) performance status score 0-2\n7. Adequate cardiac function defined as ejection fraction (EF) of ≥45% by echocardiogram or multigated acquisition (MUGA) scan.\n\n   Prior Therapy:\n8. Prior treatment-related toxicities must have resolved to ≤Grade 1 before enrolment, except for ≤Grade 2 neuropathy or alopecia.\n9. Radiation therapy: ≥60 days since TBI, craniospinal, or ≥50% pelvic radiation; ≥14 days since local palliative (small port) radiation.\n10. Stem cell infusion: ≥90 days since HSCT and ≥4 weeks since DLI.\n11. Immunotherapy: ≥28 days since prior immunotherapy (including tumor vaccines) and ≥21 days since CAR T-cell or other modified T\u002FNK cell therapy.\n12. Antileukemia therapy: ≥14 days or 5 half-lives (whichever is shorter) since last antileukemia therapy (e.g. small molecule, cytotoxic, or myelosuppressive therapy), unless otherwise specified. Hydroxyurea for cytoreduction can be initiated without restriction related to timing of study entry. Hydroxyurea can be continued concomitantly with GB3226. Please also refer to Appendix 6 that includes treatment options for the treatment of Differentiation Syndrome.\n\n    Patients may receive intrathecal chemotherapy at the time of diagnostic lumbar puncture at least 24 hours prior to the start of GB3226 and may continue prophylactic intrathecal chemotherapy beginning in Cycle 2 at the treating physician's discretion.\n13. Hematopoietic growth factors: ≥7 days since short-acting and ≥14 days since long-acting growth factor therapy.\n14. Biologics: ≥90 days or 5 half-lives (whichever is shorter) since antineoplastic biologic therapy.\n15. Steroids: ≥7 days since systemic glucocorticoids, except for physiologic doses (≤10 mg prednisone daily) or if used as cytoreductive therapy.\n16. Adequate liver and kidney function i.e., i) Estimated glomerular filtration rate (GFR) based on local institutional practice (e.g., Cockcroft-Gault formula) ≥ 60 mL\u002Fmin\u002F1.73m2 ii) Adequate liver function defined as: Total bilirubin \\\u003C1.5 times the upper limit of normal (ULN) or normal conjugated bilirubin, Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C3 times ULN (unless attributed to leukemic involvement).\n\n    Contraception\n17. Female of childbearing potential: willing to use a highly effective method of contraception or double barrier method from the time of enrolment through 180 days following the last study drug dose.\n18. childbearing potential males with female partners of agrees to use barrier contraception from the time of enrolment through 90 days following the last study drug dose.\n\n    Informed Consent\n19. Patient is able and willing to provide written informed consent and able to follow study instructions.\n\nExclusion Criteria\n\nPatients meeting any of the following criteria are NOT eligible for study participation:\n\nDiagnosis\n\n1. Diagnosis of active acute promyelocytic leukemia. (APML)\n2. Diagnosis of chronic myelogenous leukemia (CML) in blast crisis\n3. Active CNS disease (cytology, such as any blasts on cytospin, or radiography). Patients who have cleared CNS disease by at least one negative tap prior to dosing may be enrolled, and prophylactic intrathecal chemotherapy may be continued while on trial.\n\n   The following patients are required to have a lumbar puncture or Ommaya reservoir tap during the screening period:\n   1. Signs and symptoms of CNS disease\n   2. AML with monocytic phenotype\n   3. WBC ≥50,000 μL at disease presentation\n   4. History of CNS or any extramedullary disease Infection\n4. Detectable human immunodeficiency virus (HIV) viral load within the previous 6 months. Patients with a known history of HIV 1\u002F2 antibodies must have viral load testing prior to study enrolment.\n5. Hepatitis B (defined as hepatitis B virus \\[HBV\\] surface antigen positive and HBV core antibody positive, or positive HBV deoxyribonucleic acid \\[DNA\\]).\n6. Hepatitis C (defined as positive hepatitis C \\[HCV\\] antibody with reflex to positive HCV ribonucleic acid \\[RNA\\]).\n\n   NB: Patients with controlled HIV, Hep B and Hep C disease will not be excluded from study enrolment.\n\n   Pregnancy and Breast-Feeding\n7. Pregnant or nursing women. Negative serum pregnancy tests are required during Screening and a negative serum or urine pregnancy test is required within 72 hours prior to receiving the first study drug administration, in females of childbearing potential. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n   Concurrent Conditions\n\n   Cardiac Disease:\n8. Any of the following within the 6 months prior to study entry: myocardial infarction, uncontrolled\u002Funstable angina, congestive heart failure (New York Heart Association Classification Class ≥III), life-threatening, uncontrolled hypertension or arrhythmia, ischemic or severe valvular heart disease, cerebrovascular accident, or transient ischemic attack.\n9. Mean QTcF ≥450 ms for males or ≥470 ms for females on triplicate ECG. Appropriate corrections for patients with bundle branch block and those on pacemakers are allowed.\n\n   Gastrointestinal Disease:\n10. Any gastrointestinal issue of the upper GI tract likely to affect oral drug absorption or ingestion (e.g., gastric bypass, gastroparesis, etc.).\n11. Cirrhosis with a Child-Pugh score of B or C.\n12. Graft-Versus-Host Disease (GVHD): Signs or symptoms of acute or chronic GVHD \\> Grade 2 within 4 weeks of enrolment. All transplant patients must have been off all systemic immunosuppressive therapy and calcineurin inhibitors for at least 4 weeks prior to enrolment. Patients may be on physiological doses of steroids (≤10 mg\u002Fday).\n13. Concurrent malignancy in the previous 2 years, with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ, melanoma in situ) treated with potentially curative therapy, or concurrent low-grade lymphoma, that is asymptomatic and lacks bulky disease and shows no evidence of progression, and for which the patient is not receiving any systemic therapy or radiation.\n14. Concurrent malignancy must be in complete remission (CR) or no evidence of disease (NED) during this timeframe.\n15. Pre-existing disorder predisposing the patient to a serious or life-threatening infection (e.g. cystic fibrosis, congenital or acquired immunodeficiency, bleeding disorder, or cytopenias not related to AML).\n16. Acute or chronic systemic fungal, bacterial, viral, or other infection which is uncontrolled.\n17. Major surgery within 4 weeks prior to the first dose of GB3226.\n18. History of or any concurrent condition, therapy, laboratory abnormality, or allergy to excipients (see formulation details in Investigator Brochure) that in the Investigator's opinion might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate.\n\n    Concomitant Medications and Interventions\n19. Any commercially available or investigational antileukemic therapy other than GB3226, with the following exceptions:\n\n    * Short-term administration of corticosteroids and\u002For hydroxyurea for cytoreduction. Alternative cytoreductive agents as judged by the treating physician after consultation with study physician may be applied - see also Appendix 6.\n    * Intrathecal chemotherapy for CNS prophylaxis is permitted, at the treating physician's discretion. In the Phase 1 DLT evaluable cohort, CNS prophylaxis may continue starting in C2D1.\n    * Receipt of an investigational agent within 30 days of starting GB3226, unless inclusion criteria 9-13, then the longer period must be applied. Patients may continue with noninterventional follow-up from previous clinical studies.\n    * Any concurrent systemic treatment to prevent GVHD.\n20. The following Exclusions apply related to concomitant use of CYP3A4 inhibitors or inducers:\n\nPhase 1:\n\nCohort A: Arm E: Concurrent use of weak, moderate, and strong inhibitors or inducers of CYP3A4, which should be discontinued at least 7 days prior to enrolment.\n\nCohort B: Concurrent use of weak, moderate and strong CYP3A4 inhibitors\u002Finducers (except for systemic itraconazole, ketoconazole, posaconazole, or voriconazole, which should have been started at least 7 days prior to enrolment). Other weak, moderate or strong inhibitors or inducers of CYP3A4 should be discontinued at least 7 days prior to enrolment Cohort C: Concurrent use of weak, moderate, and strong inhibitors or inducers of CYP3A4, except for isovuconazole or fluconazole, which should have been started at least 7 days prior to enrolment. All other CYP3A4 inhibitors should be discontinued at least 7 days prior to enrolment.\n\nPhase 2:\n\nPatients who will not be receiving GB3226 in combination with a CYP3A4 inhibitor antifungal must discontinue all CYP3A4 inhibitors at least 7 days prior to the first dose of GB3226. These patients will receive the GB3226 RP2D established for administration without a CYP3A4 inhibitor as determined in the Phase 1 part of the study.\n\nPatients who will be receiving GB3226 in combination with a CYP3A4 inhibitor antifungal must have initiated the antifungal treatment at least 24 hours prior to enrolment. These patients will receive the GB3226 RP2D established for co-administration with a CYP3A4 inhibitor as determined in the Phase 1 part of the study.\n\nNote: The RP2D for GB3226 for patients on a CYP3A4 inhibitor versus patients who are not on a CYP3A4 inhibitor may be different.",{"count":99,"type":20},184,[77,101],"PHASE2","Study GB3226-DEV-001 is a Phase 1\u002F2, open-label, dose-escalation and expansion study of GB3226 in the treatment of relapsed or refractory acute myeloid leukaemia",[26],"2025-07-17",{"date":106,"type":31},"2025-07-24",{"date":108,"type":20},"2026-06-10",{"date":110,"type":20},"2029-10-10",{"name":112,"class":38},"Galecto Biotech AB",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":15,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":39},"100582896","phase-2-thiotepa-combined-with-busulfan-and-fludarabine-conditioning-regimen-for-haploidentical-hematopoietic-stem-cell-transplantation-in-elderly-patients-with-high-risk-acute-myeloid-leukemia-100582896","NCT06869265","Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia","A Multicenter, Single-Arm, Prospective Clinical Study of Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia","Inclusion Criteria:\n\n1. Age 55-70 years (inclusive).\n2. Diagnosis of high-risk AML , include relapsed\u002Frefractory AML or CR MRD+ or ELN22 adverse risk group . Relapsed\u002Frefractory AML defined as at least one of the following: recurrence of leukemia cells in peripheral blood or bone marrow blasts \\>5% after complete remission (CR), failure to achieve remission after two courses of standard induction therapy, relapse within 12 months after consolidation therapy, relapse after 12 months that is refractory to conventional chemotherapy, multiple relapses, or persistent extramedullary leukemia .\n3. Scheduled to undergo haploidentical hematopoietic stem cell transplantation (haplo-HSCT).\n4. Adequate organ function.\n5. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n6. Written informed consent obtained.\n\nExclusion Criteria:\n\n1. Unwillingness or refusal to accept the study treatment protocol.\n2. Presence of donor-specific anti-HLA antibodies.\n3. Known human immunodeficiency virus (HIV) infection.\n4. Active hepatitis B or C, or chronic active hepatitis.\n5. Uncontrolled active infection at the time of enrollment.\n6. Any other condition deemed by the investigator as unsuitable for study inclusion.","55 Years","70 Years",{"count":123,"type":20},56,[101],"Abstract:\n\nThis clinical study is designed to evaluate the efficacy and safety of a thiotepa, busulfan, and fludarabine (TBF) conditioning regimen for haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in elderly patients (≥55 years) with high-risk acute myeloid leukemia (AML). A total of 56 eligible patients will be enrolled in this prospective, single-arm, multicenter trial.\n\nStudy Design:\n\nThis is a multicenter, single-arm, prospective clinical trial. Eligible patients will receive the following conditioning regimen: thiotepa 5 mg\u002Fkg\u002Fday on Days -10 to -9; busulfan 3.2 mg\u002Fkg\u002Fday on Days -8 to -6; fludarabine 30 mg\u002Fm²\u002Fday on Days -6 to -2; and rabbit anti-thymocyte globulin (rATG) 1.5-2.5 mg\u002Fkg\u002Fday on Days -5 to -2. Hematopoietic stem cell infusion will be performed on Day 0. Graft-versus-host disease (GVHD) prophylaxis will include cyclosporine A (CsA), mycophenolate mofetil (MMF), and methotrexate (MTX). The primary endpoint of this study is 1-year relapse-free survival (RFS).\n\nInclusion Criteria:\n\nAge 55-70 years (inclusive). Diagnosis of high-risk AML , include relapsed\u002Frefractory AML or CR MRD+ or ELN22 adverse risk group .Relapsed\u002Frefractory AML defined as at least one of the following: recurrence of leukemia cells in peripheral blood or bone marrow blasts \\>5% after complete remission (CR), failure to achieve remission after two courses of standard induction therapy, relapse within 12 months after consolidation therapy, relapse after 12 months that is refractory to conventional chemotherapy, multiple relapses, or persistent extramedullary leukemia）.\n\nScheduled to undergo haploidentical hematopoietic stem cell transplantation (haplo-HSCT).\n\nAdequate organ function. Eastern Cooperative Oncology Group (ECOG) performance status ≤2. Written informed consent obtained.\n\nExclusion Criteria:\n\nUnwillingness or refusal to accept the study treatment protocol. Presence of donor-specific anti-HLA antibodies. Known human immunodeficiency virus (HIV) infection. Active hepatitis B or C, or chronic active hepatitis. Uncontrolled active infection at the time of enrollment. Any other condition deemed by the investigator as unsuitable for study inclusion.",[127,128,26],"Acute Myeloid Leukemia (AML)","High Risk Acute Myeloid Leukemia(AML)","2025-05-15",{"date":131,"type":31},"2025-05-18",{"date":133,"type":31},"2025-05-01",{"date":135,"type":20},"2029-04-01",{"name":137,"class":66},"Peking University People's Hospital",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":21,"phases":148,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":165},"100490190","phase-1-genetic-ablation-of-cd33-in-hsc-to-broaden-the-therapeutic-index-of-cd33-directed-immunotherapy-in-patients-with-aml-100490190","NCT05662904","Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML","Genetic Ablation of CD33 in Hematopoietic Stem Cells to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with Acute Myeloid Leukemia (AML)","GALAXY33","Key Inclusion Criteria:\n\n* confirmed AML according to the WHO classification\n* relapsed disease after allo-SCT from an HLA-identical family donor (≥ 2 months after allo-SCT at time of inclusion)\n* ≤ 29% of bone marrow blasts as detected by cytomorphology or immunohistochemistry\n* age ≥ 18 years\n* confirmed CD33 expression on leukemic blasts at current relapse (as detected by flow cytometry)\n* adequate organ function:\n\n  * Renal function defined as: serum creatinine of ≤ 2x ULN or eGFR ≥ 30 mL\u002Fmin\u002F1.73 m2\n  * Liver function defined as:\n\n    * ALT ≤ 3 times the ULN for the respective age\n    * Bilirubin ≤ 2.0 mg\u002Fdl with the exception of patients with hyperbilirubinemia explained by Gilbert-Meulengracht syndrome (may be included if total bilirubin is ≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN) or extrahepatic disease (e.g. chronic hemolytic anemia)\n* Minimum level of pulmonary reserve defined as ≤ grade 1 dyspnea and pulse oxygenation \\> 90% on room air\n* Hemodynamic stability and LVEF ≥ 40% as confirmed by echocardiogram\n* Absolute lymphocyte count (ALC) ≥ 100\u002Fmm3\n\nKey Exclusion Criteria:\n\n* ECOG performance status \\>2\n* Confirmed CNS involvement\n* Acute or chronic Graft versus Host disease (GvHD)\n* Availability of other curative standard treatment options\n* Prior treatment with GO\n* Prior hepatic veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS)\n* Uncontrolled active hepatitis B or C\n* HIV-positivity\n* Uncontrolled bacterial, viral or fungal infection\n* Participation in another clinical trial at the time of screening\n* Organ dysfunction (liver, kidney, lung, heart) that is a contraindication for conditioning therapy\n* Severe concomitant disease (e.g. uncontrolled arterial hypertension, heart failure NYHA III-IV, uncontrolled diabetes mellitus, uncontrolled hyperlipidemia)\n* Unstable angina and\u002For myocardial infarction within 3 months prior to screening\n* Pregnant or nursing (lactating) women",{"count":147,"type":20},12,[77],"The study \"GALAXY33\" is an open-label, prospective, nonrandomized, one arm phase I clinical trial in which patients with relapsed AML after allogeneic hematopoietic stem cell transplantation will be transplanted with CD33-deleted CD34+ HSC derived from the initially matched family donor.",[26],[152,153,154,155],"AML","allogeneic stem cell transplantation","gene editing","chemotherapy resistance","2025-03-12",{"date":158,"type":31},"2025-03-14",{"date":160,"type":20},"2028-01",{"date":162,"type":20},"2030-01",{"name":164,"class":66},"German Cancer Research Center",2,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":39},"100519908","phase-1-a-phase-1-clinical-trail-of-ntq2494-tablets-in-patients-with-advanced-hematological-malignancies-100519908","NCT06049667","A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies","A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic\u002FPharmacodynamic Characteristics and Preliminary Efficacy of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies","Inclusion Criteria:\n\n1. ≥18 years in age, male or female.\n2. Relapsed\u002Frefractory AML patients.\n3. ECOG performance status score is 0 to 2.\n4. Life expectancy of at least 3 months.\n5. Adequate bone marrow and good organ function.\n6. Ability to understand the purpose and risks of the study and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Receiving anticancer therapy including immunotherapy, targeted therapy, endocrine therapy, radiotherapy and chemotherapy within 2 weeks or 5 half-lives (whichever is longer) prior to starting study treatment.\n2. Receiving any other investigational agents within 4 weeks prior to starting study treatment.\n3. Having major surgery within 4 weeks prior to starting study treatment, or intended to undergo surgery during the trail.\n4. AML with any of the following: 1) acute promyelocytic leukemia; 2) AML with blast crisis of chronic myelogenous leukemia; 3) central nervous system leukemia.\n5. Prior or current other malignancy (except cured noninvasive basal cell or squamous cell skin cancer and\u002For other cured carcinoma in situ; except for other malignancies that have achieved clinical cure for \\> 5 years and have not recurred within 5 years).History of severe cardiovascular or cerebrovascular disease.\n6. Use of strong inhibitors or strong inducers of CYP3A4 or P-gp within 7 days prior to starting study treatment.\n7. Receiving (attenuated) live vaccines within 4 weeks prior to starting study treatment and\u002For planning to receive (attenuated) live vaccines during the trial.\n8. With unresolved clinically significant non-hematological toxicities from prior AML therapy (chemotherapy, targeted therapy, immunotherapy, radiotherapy and surgery), defined as any grade 2 or higher grade (CTCAE v5.0), alopecia and other events that are tolerable as judged by the investigator.\n9. Patients who have received previous allogeneic hematopoietic stem cell transplantation; or received autologous hematopoietic stem cell transplantation within 3 months prior to starting study treatment.\n10. Unable to swallow oral tablets, or other conditions seriously affecting gastrointestinal absorption judged by the investigator.\n11. Patients with uncontrolled infections unsuitable for the trail judged by the investigator.\n12. Known infection with hepatitis B, hepatitis C, HIV or Syphilis.\n13. Known alcohol or drug dependence.\n14. Patients with mental disorders or poor compliance.\n15. Patients with a previous history of severe allergy to any drug or food.\n16. Lactating or pregnant female, and females or males (or partners) who plan to pregnant and do not agree to use adequate contraception for the duration of the trail and up to 3 months after completion of the last study treatment.\n17. Other reasons judged by the investigator that the patients unsuitable for the trail.",{"count":174,"type":20},72,[77],"NTQ2494 tablet, an anti-tumor molecular targeted drug, is an AXL kinase inhibitor.\n\nThe objectives were to evaluate the safety and tolerability, PK characteristics and preliminary efficacy of NTQ2494 tablets in patients with advanced hematological malignancies.",[26],"2023-09-17",{"date":180,"type":31},"2023-09-22",{"date":182,"type":31},"2023-08-07",{"date":184,"type":20},"2026-08",{"name":186,"class":38},"Nanjing Chia-tai Tianqing Pharmaceutical"]